haematology

News in Brief: Novel r/r MM treatment shows promising efficacy, sustained durability; Shingrix effective after HSCT; Convalescent plasma ineffective even when used early in COVID-19

Novel r/r MM treatment shows promising efficacy, sustained durability A novel therapy for relapsed or refractory multiple myeloma has shown promising efficacy and tolerability that could offer a new treatment approach, say researchers who will move to phase 2 testing. Researchers collaborating from the US, Spain and France report in The Lancet that the bispecific ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic